160 related articles for article (PubMed ID: 10634133)
1. Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype.
Wennerholm A; Johansson I; Massele AY; Lande M; Alm C; Aden-Abdi Y; Dahl ML; Ingelman-Sundberg M; Bertilsson L; Gustafsson LL
Pharmacogenetics; 1999 Dec; 9(6):707-14. PubMed ID: 10634133
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity.
Wennerholm A; Johansson I; Hidestrand M; Bertilsson L; Gustafsson LL; Ingelman-Sundberg M
Pharmacogenetics; 2001 Jul; 11(5):417-27. PubMed ID: 11470994
[TBL] [Abstract][Full Text] [Related]
3. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs.
Masimirembwa C; Hasler J; Bertilssons L; Johansson I; Ekberg O; Ingelman-Sundberg M
Eur J Clin Pharmacol; 1996; 51(2):117-22. PubMed ID: 8911874
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
5. The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity.
Wennerholm A; Dandara C; Sayi J; Svensson JO; Abdi YA; Ingelman-Sundberg M; Bertilsson L; Hasler J; Gustafsson LL
Clin Pharmacol Ther; 2002 Jan; 71(1):77-88. PubMed ID: 11823760
[TBL] [Abstract][Full Text] [Related]
6. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.
Bathum L; Skjelbo E; Mutabingwa TK; Madsen H; Hørder M; Brøsen K
Br J Clin Pharmacol; 1999 Sep; 48(3):395-401. PubMed ID: 10510152
[TBL] [Abstract][Full Text] [Related]
7. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity.
Masimirembwa C; Persson I; Bertilsson L; Hasler J; Ingelman-Sundberg M
Br J Clin Pharmacol; 1996 Dec; 42(6):713-9. PubMed ID: 8971426
[TBL] [Abstract][Full Text] [Related]
8. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population.
Roh HK; Dahl ML; Johansson I; Ingelman-Sundberg M; Cha YN; Bertilsson L
Pharmacogenetics; 1996 Oct; 6(5):441-7. PubMed ID: 8946476
[TBL] [Abstract][Full Text] [Related]
9. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles.
Leathart JB; London SJ; Steward A; Adams JD; Idle JR; Daly AK
Pharmacogenetics; 1998 Dec; 8(6):529-41. PubMed ID: 9918137
[TBL] [Abstract][Full Text] [Related]
10. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians.
Droll K; Bruce-Mensah K; Otton SV; Gaedigk A; Sellers EM; Tyndale RF
Pharmacogenetics; 1998 Aug; 8(4):325-33. PubMed ID: 9731719
[TBL] [Abstract][Full Text] [Related]
11. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans.
Gaedigk A; Bradford LD; Marcucci KA; Leeder JS
Clin Pharmacol Ther; 2002 Jul; 72(1):76-89. PubMed ID: 12152006
[TBL] [Abstract][Full Text] [Related]
12. Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes.
Dalén P; Dahl ML; Eichelbaum M; Bertilsson L; Wilkinson GR
Pharmacogenetics; 1999 Dec; 9(6):697-706. PubMed ID: 10634132
[TBL] [Abstract][Full Text] [Related]
13. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.
Marandi T; Dahl ML; Rägo L; Kiivet R; Sjöqvist F
Eur J Clin Pharmacol; 1997; 53(3-4):257-60. PubMed ID: 9476041
[TBL] [Abstract][Full Text] [Related]
14. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M
J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380
[TBL] [Abstract][Full Text] [Related]
15. Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden.
Aklillu E; Herrlin K; Gustafsson LL; Bertilsson L; Ingelman-Sundberg M
Pharmacogenetics; 2002 Jul; 12(5):375-83. PubMed ID: 12142727
[TBL] [Abstract][Full Text] [Related]
16. Debrisoquine and mephenytoin oxidation in Sinhalese: a population study.
Weerasuriya K; Jayakody RL; Smith CA; Wolf CR; Tucker GT; Lennard MS
Br J Clin Pharmacol; 1994 Nov; 38(5):466-70. PubMed ID: 7893590
[TBL] [Abstract][Full Text] [Related]
17. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.
Dorado P; Berecz R; Cáceres MC; González I; Cobaleda J; Llerena A
Clin Chem Lab Med; 2005; 43(3):275-9. PubMed ID: 15843230
[TBL] [Abstract][Full Text] [Related]
18. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
Johansson I; Lundqvist E; Bertilsson L; Dahl ML; Sjöqvist F; Ingelman-Sundberg M
Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11825-9. PubMed ID: 7903454
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.
Sachse C; Brockmöller J; Bauer S; Roots I
Am J Hum Genet; 1997 Feb; 60(2):284-95. PubMed ID: 9012401
[TBL] [Abstract][Full Text] [Related]
20. Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians.
Dalén P; Dahl ML; Roh HK; Tybring G; Eichelbaum M; Wilkinson GR; Bertilsson L
Br J Clin Pharmacol; 2003 Jun; 55(6):630-4. PubMed ID: 12814461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
